Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Relief therapeutics Holding
Volgen
Gerardke schreef op 30 augustus 2021 17:22 :
[...]
DeZwarteRidder 6 augustus 2021 14:31
Humanigen wacht op goedkeuring FDA
Humanigen (HGEN) op $16
Wie van een beetje avontuur houdt kan met het aandeel Humanigen mikken op een goedkeuring van de FDA. We geven rond uit toe dat het speculatief is. Verkopen doet u bij teleurstelling, maar ook bij de eerste euforie. Dit aandeel is geen kernbelegging, maar interessant is het zeker.
....yeps...
Jouw avontuurtje met Humanigen is alvast gedaan , Weeral slecht advies van jou !! Humanigen Inc. has added a new press release to its website: FDA has declined Humanigen’s Emergency Use Authorization (EUA) Request for Lenzilumab in Hospitalized COVID-19 Patients
DeZwarteRidder schreef op 8 september 2021 08:32 :
[...]
Deze dumpovereenkomst met GEM gaat dus niet door, want Relief en GEM hebben grote ruzie.
GEM zou met een vaste winst van 10% tot 50 miljoen CHF aandelen mogen dumpen.
Door de koersdaling worden dat theoretisch ca 2% meer aandelen, maar in werkelijkheid krijgt GEM geen enkel aandeel erbij.
In plaats van deze dumpdeal is Relief nu zelf bezig om bijna dagelijks aandelen te dumpen.
Waar heb je die info dat GEM en RLF grote ruzie hebben? Bron? Ik heb enkel weet van RLF versus NRX maar niet met GEM
Beso schreef op 9 september 2021 09:41 :
[...]
Waar heb je die info dat GEM en RLF grote ruzie hebben?
Bron?
Ik heb enkel weet van RLF versus NRX maar niet met GEM
Dat gaan ze niet aan de grote klok hangen, maar het is volkomen duidelijk voor mij. Relief is zo boos op GEM dat ze zelf aandelen gaan dumpen op de beurs, terwijl ze een deal hadden met GEM. De dumpdeal met GEM is dus waardeloos geworden en bovendien daalt de waarde van de Relief-aandelen door het gedump van Relief. Tenslotte heeft GEM NRX in contact gebracht met Relief.
Gerardke schreef op 9 september 2021 07:35 :
[...]
Jouw avontuurtje met Humanigen is alvast gedaan , Weeral slecht advies van jou !!
Humanigen Inc. has added a new press release to its website:
FDA has declined Humanigen’s Emergency Use Authorization (EUA) Request for Lenzilumab in Hospitalized COVID-19 Patients
Ik heb geen enkel 'advies' gegeven inzake Humanigen. Ik volg het niet eens. Ik heb alleen een artikel geplaatst van iemand anders over een concurrent van Relief.
DeZwarteRidder schreef op 9 september 2021 10:02 :
[...]
Dat gaan ze niet aan de grote klok hangen, maar het is volkomen duidelijk voor mij.
Relief is zo boos op GEM dat ze zelf aandelen gaan dumpen op de beurs, terwijl ze een deal hadden met GEM.
De dumpdeal met GEM is dus waardeloos geworden en bovendien daalt de waarde van de Relief-aandelen door het gedump van Relief.
Tenslotte heeft GEM NRX in contact gebracht met Relief.
Zij vertellen dus niets , maar jij weet het ? Van wie ? Waarom 5 verkopen gedaan van 18000 € /stuk .. dat is dumpen .. wacht dan tot ik mijn aandelen verkoop ;-))) En Relief is boos op Gem en daarom dumpen ze hun eigen aandelen ?? Gekker gaat het niet worden
Humanigen heeft drie dagen voor Relief EUA aangevraagd. We zullen het binnenkort dus wel horen. Relief staat er trouwens veel beter voor , op wat diarree na ;-)
Gerardke schreef op 9 september 2021 12:54 :
[...]Zij vertellen dus niets , maar jij weet het ? Van wie ? Waarom
5 verkopen gedaan van 18000 € /stuk .. dat is dumpen .. wacht dan tot ik mijn aandelen verkoop ;-)))
En Relief is boos op Gem en daarom dumpen ze hun eigen aandelen ?? Gekker gaat het niet worden
Ik kan wel zien dat jij weinig inzicht hebt in dit soort zaken. Je moet tussen de regels door lezen. De berichten zijn voor mij glashelder.
Management Transactions Data submitted by listed companies regarding management transactions. Type of Transaction 10 results 03.09.2021 RELIEF THERAPEUTICS Holding SA Sale Registered shares 79'094 CHF 14'158.00 26.08.2021 RELIEF THERAPEUTICS Holding SA Sale Registered shares 100'000 CHF 18'500.00 25.08.2021 RELIEF THERAPEUTICS Holding SA Sale Registered shares 100'000 CHF 18'500.00 24.08.2021 RELIEF THERAPEUTICS Holding SA Sale Registered shares 100'000 CHF 18'550.00 23.08.2021 RELIEF THERAPEUTICS Holding SA Sale Registered shares 100'000 CHF 18'500.00 20.08.2021 RELIEF THERAPEUTICS Holding SA Sale Registered shares 100'000 CHF 18'500.00 19.08.2021 RELIEF THERAPEUTICS Holding SA Sale Registered shares 100'000 CHF 19'900.00 18.08.2021 RELIEF THERAPEUTICS Holding SA Sale Registered shares 100'000 CHF 18'500.00 17.08.2021 RELIEF THERAPEUTICS Holding SA Sale Registered shares 100'000 CHF 18'500.00 10.08.2021 RELIEF THERAPEUTICS Holding SA Sale Registered shares 500'000 CHF 105'066.55 © 2020 SIX Exchange
Relief heeft nog 574'903'701 (13.065%) eigen aandelen in bezit die allemaal gedumpt gaan worden omdat Relief geld nodig heeft om de salarissen te betalen.
DeZwarteRidder schreef op 9 september 2021 13:09 :
Relief heeft nog 574'903'701 (13.065%) eigen aandelen in bezit die allemaal gedumpt gaan worden omdat Relief geld nodig heeft om de salarissen te betalen.
antwoord van Relief : Michael Miller 18:14 (31 minuten geleden) aan mij, contact@relieftherapeutics.com , Relief Please see the link to a press release explaining the plan to sell treasury shares relieftherapeutics.com/newsblog/relie... Board of Directors approved an increase of the Company's registered share capital from 3,246,727,248 to 3,371,727,248 shares through the issuance of 125,000,000 shares at an issue price of CHF 0.01. The 125,000,000 new shares, to be issued out of the Company’s authorized capital, are fully subscribed for by Relief Therapeutics International SA, its 100% wholly owned subsidiary, and will be listed on the SIX Swiss Exchange on or around March 11, 2021. Execution of the transaction will provide Relief with treasury shares, offering greater financial flexibility to raise funds in an efficient manner and in line with its equity plans for the Company and its subsidiaries. Michael K. Miller Vice President Investor Relations 917.633.6086 Direct 203.536.8136 Mobilemmiller@rxir.com Rx Communications Group, LLC
Relief and AdVita Close Definitive Agreement for Relief to Acquire All Outstanding Shares of AdVita Acquisition Expands Scope of Development of Inhaled Formulation of Aviptadil Geneva, Switzerland, July 28, 2021 – RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, today announced that it has closed a definitive agreement to acquire all outstanding shares of AdVita Lifescience GmbH ("AdVita"), a Germany-based, privately held pharmaceutical company developing effective products and strategies to improve the treatment and diagnosis of rare lung diseases. With the acquisition, Relief has gained additional pending intellectual property rights that may cover RLF-100TM inhaled formulation specifications and the potential application of inhaled aviptadil for the treatment of lung diseases such as acute respiratory distress syndrome (ARDS), pulmonary sarcoidosis and checkpoint inhibitor-induced pneumonitis (CIP). Under the terms of the agreement, Relief paid AdVita shareholders a total of 135,741,063 Relief common shares, representing EUR 25 million in value based on a 60-day Volume-Weighted Average Price (VWAP) of Relief’s common stock, to acquire all outstanding shares of AdVita. In addition, Relief will pay milestone payments of up to EUR 20 million in cash, contingent to achievement of certain regulatory milestones related to AdVita’s development programs.
Relief Announces Issuance of Shares from Authorized Capital as Approved by 2021 Annual General Meeting Ad Hoc Announcement pursuant to Art. 53 LR, 22 July 2021 Relief Announces Issuance of Shares from Authorized Capital as Approved by 2021 Annual General Meeting Shares being used in part for payments related to AdVita and APR acquisitions Acquisitions are part of Relief’s transformation into a fully integrated diversified commercial-stage pharmaceutical company Geneva, Switzerland, July 22, 2021 – RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (“Relief” or the “Company”), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the Company will, on or around July 27, 2021, issue 1,000,000,000 additional registered shares out of the authorized share capital approved by the Annual General Meeting on June 18, 2021. The new shares are fully subscribed at par value by the Company’s wholly owned subsidiary, Relief Therapeutics International SA, and will be listed on the SIX Swiss Exchange on or around July 28, 2021. Some of the shares will be used for contractually agreed payments to the respective sellers of AdVita Lifescience GmbH (“AdVita”) and APR Applied Pharma Research SA (“APR”): approximately 140,000,000 shares and 206,786,784 shares, respectively. The remaining new shares will be held as treasury shares for possible future financing transactions, acquisitions, general corporate purposes, and the settlement of possible future contingent milestone payments to the APR and AdVita sellers. The APR sellers are generally subject to a 75-day lock-up period and a subsequent leak-out schedule.
Relief Therapeutics Announces CHF 15 Million Private Placement Ad Hoc Announcement pursuant to Art. 53 LR, 26 July 2021 Relief Therapeutics Announces CHF 15 Million Private Placement Geneva, Switzerland, July 26, 2021 –RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, today announced that it has entered into a definitive agreement with two U.S. institutional investors to purchase in a private placement an aggregate of 71,428,572 shares of Relief common stock at a purchase price of CHF 0.21 per share. The aggregate gross proceeds from the private placement are expected to be approximately CHF 15 million, before deducting the placement agent fees and offering expenses payable by Relief. The private placement offering is expected to close on or about July 28, 2021, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. Relief plans to use the net proceeds from the private placement to acquire additional assets to expand and diversify its drug pipeline, meet its obligations to pay potential milestone payments and for general corporate purposes. Jack Weinstein, Chief Financial Officer and Treasurer of Relief, said: “This financing provides us with significant additional flexibility to both meet our potential future milestone payments for Acer Therapeutics Inc., APR Applied Pharma Research SA and AdVita Lifescience GmbH, while also expanding our ability to grow our pipeline. Chief among our priorities is moving ahead with our plan to further the development of RLF-100TM worldwide, as vaccine acceptance issues and new COVID-19 variants make the need for an effective therapy as great as ever.” The private placement shares will be trading on the SIX Swiss Exchange and ranking pari passu (carrying the same rights) with Relief’s existing shares, and will be delivered from Relief’s treasury shares that were issued out of its authorized share capital under exclusion of the existing shareholders’ pre-emptive rights.
Relief Therapeutics’ Wholly Owned Subsidiary, APR Applied Pharma Research, Launches PKU GOLIKE® KRUNCH in Germany and Italy
Gerardke schreef op 9 september 2021 23:08 :
Relief Therapeutics’ Wholly Owned Subsidiary, APR Applied Pharma Research, Launches PKU GOLIKE® KRUNCH in Germany and Italy
lol Dat gaat Relief redden.....!!!
[quote alias=DeZwarteRidder id=13669074 date=202109092315] [...] lol Dat gaat Relief redden.....!!! I quote "Freek" www.youtube.com/watch?v=H6uPe7Euzd8&a...
Gerardke schreef op 10 september 2021 08:40 :
[quote alias=DeZwarteRidder id=13669074 date=202109092315]
[...]lol
Dat gaat Relief redden.....!!!
I quote "Freek"
www.youtube.com/watch?v=H6uPe7Euzd8&a... Freek Vonk.....???
Het is toch wel grappig dat het verbreden van de portfolio de eerste kleine resultaten begint op te leveren.
jazeker, al wel zo 3 a 4 jaar geleden, en sinds aantal maanden met Relief, kwestie van gewoon jou commentaar negeren. doe eens niet zo onaardig tegen iedereen, zelfs al heb je weleens gelijk, een gelukkig mens is niet onaardig.
Iemand bij yahoo kwam dit melden: Mystery solved! The 8K Sept 10 filing tells us why the overloaded regional hospitals had such a high death rate for VIP and placebo patients. The 8K says: "This data suggest that the IL-6 cytokine data document biologic effect across all patients and sites, even though the ultimate therapeutic result is dependent upon state-of the-art ICU care and specifically dependent upon not terminating life support on salvageable patients for the purposes of resource allocation." So the ICU's turned off the life support! -----De patiënten die aviptadil kregen in het onderzoek zouden de behandeling gestopt hebben gekregen omdat minder zieke patiënten de beademing nodig hadden.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee